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Abstract
Objective: Peroxisome proliferator activated receptors (PPARs), known regulators of lipid homeostasis in different tissues,
are crucial during placental development. In this work, we aim to determine whether PPARs activation modulates lipid
metabolism in the placenta from control and diabetic experimental models at midgestation.
Materials and Methods: Placental explants obtained from control and neonatal-streptozotocin-induced- diabetic rats on day
13.5 of gestation were cultured in the presence or absence of ligands of the three PPARs isoforms (clofibrate, 15-deoxyδ 12,14
prostaglandin J2 and carbaprostacyclin; which are PPARα, PPARγ and PPARδ agonists respectively) for further analysis of
lipid metabolism. Lipid levels (triglycerides, cholesterol, cholesteryl esters and phospholipids) were analysed by thin layer
chromatography, de novo lipid synthesis was assessed by incorporation of 14C-acetate as a tracer, and lipid catabolism was
studied through the evaluation of glycerol release.
Results: Placental tissues from diabetic rats showed increased triglycerides and cholesteryl ester levels, decreased de novo
lipid synthesis and enhanced lipid catabolism when compared to controls. PPARα activation reduced lipid levels and synthesis,
and increased lipid catabolism in the placenta. PPARγ activation did not modify placental lipid mass and catabolism, but
significantly reduced de novo lipid synthesis. PPARδ ligands reduced phospholipid levels and de novo lipid synthesis, and
increased placental lipid catabolism.
Discussion: These results provide evidence of novel PPARs functions as regulators of placental lipid metabolism, a first step
in the understanding of pathways that may allow the regulation of placental lipid metabolism and the prevention of the
lipid overload transferred to the developing fetus in maternal diabetes.
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Özet
Hücre Çekirde¤inde Peroksizom Ço¤alt›c› Reseptörlerin Hareketlendirilmesi Plasentada
Lipid Metabolizmas›n› Düzenliyor
Amaç: Peroksizom ço¤alt›c› hareketlendirilmifl reseptörleri (PPAR), de¤iflik dokularda lipid dengelerinin bilinen
düzenleyicileri olup, plasenta geliflmesinde çok önemlidirler. Bu çal›flmada, PPAR hareketlendirilmesinin normalde ve fleker
hastal›¤›nda plasentada lipid metabolizmas›n› de¤ifltirip de¤ifltirmedi¤inin saptanmas› amaçlanm›flt›r.
Materyal ve Metot: Neonatal-streptozotosinle fleker hastal›¤› oluflturulan s›çanlar ve normal kontrollerden gebeli¤in 13.5’inci
günü al›nan plasentalarla kültür yap›ld›. Kültürlere PPAR’nin üç benzer türü olan PPARα, PPARγ ve PPARδ’ya ba¤lanarak
hareketlendirilen klorofibrat, 15-deoksiδ12,14 prostaglandin J2 ve karbaprostasiklin kat›larak veya kat›lmayarak lipid metabo-
lizmas› incelendi. Trigliseridler, kolesterol, kolesteril esterleri ve fosfolipidlerince tabak kromatografisi ile ayr›larak ölçüldüler,
de novo lipid sentezi 14C-asetat izleyici ba¤lanmas› ile saptand› ve lipid katabolizmas› gliserol sal›n›m ile ölçüldü.
Sonuçlar: fieker hastal›¤› oluflturulan s›çanlar›n plasentalar›nda trigliseridlerin ve kolesteril esterlerinin düzeyi yüksek ancak
de novo lipid yap›m› ve lipid katabolizmas› kontrollere k›yasla düflüktü. PPARγ hareketlendirilmesi plasentada lipid kütlesini
ve katabolizmas›n› de¤ifltirmedi ancak de novo lipid yap›m›n› önemli ölçüde azatt›. PPARδ ba¤lay›c›lar, fosfolipid düzeyini ve
de novo lipid yap›m›n› azaltt›lar ve plasentada lipid katabolizmas›n› yükselttiler.
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The placenta is an essential organ that transports the needed
nutrients and oxygen from the mother to the fetus. Develop-
mental, functional and structural anomalies in the placenta
from diabetic pregnancies are considered in part responsible
for several fetal complications that arise in this pathology (1).
In diabetic pregnancies, fetal overgrowth or macrosomia are
consequences of increased maternal glucose, which stimulates
fetal insulin production (2). Combined with the permissive
environment of fetal hyperinsulinemia, excessive availability
of different maternal nutrients to the placenta has been related
to increased fetal adiposity and overgrowth (3). Indeed,
there is a correlation between the maternal serum lipid levels
and the fetal lipid accretion in diabetic pregnancies, an alte-
ration related with both macrosomia and the intrauterine
programming of glucose intolerance in the neonate (4,5).
Lipid transfer to the developing fetus is highly regulated
within the placenta. Although there is no direct transfer of es-
terified lipids from maternal to fetal circulation, lipoprotein
receptors, lipoprotein lipase activity and intracellular lipase
activity are present in placental tissues. The lipids are taken
up, catabolised, re-esterified and stored transiently within the
placenta, until being re-catabolised for further free fatty acid
release into the fetal circulation (6).
The regulatory pathways that control placental lipid metabo-
lism are poorly understood, and we hypothesised that peroxi-
some proliferator activated receptors (PPARs) may be
important regulators of placental lipid homeostasis.
PPARs are members of the nuclear hormone receptor super-
family of ligand-dependent transcription factors, deeply
involved in adipocyte differentiation and lipid homeostasis
(7). The three identified subtypes, named PPARα, PPARγ
and PPARδ, interact with specific DNA response elements
within promoter regions of target genes as complexes with
the 9-cis-retinoic acid receptor (RXR). When activated by
agonist-ligand binding, the heterodimer complex recruits
transcription co-activators and regulates the transcription of
genes involved in lipid and carbohydrate metabolism,
inflammatory responses and developmental processes (8).
The PPAR subtypes have several endogenous agonists such
as prostaglandins, leukotrienes and polyunsaturated fatty
acids. On the other hand, both thiazolidinediones and
fibrates are pharmacological PPAR ligands utilised in the
treatment of obesity, dyslipemias and diabetes (9).
The three PPAR isotypes have been localised in placental
cells. Moreover, PPARγ and PPARδ are essential genes for
placental development, and their inactivation induces pro-
found anomalies in the vasculature and structure of the laby-
rinth zone that leads to fetal death by midgestation (10,11).
In the present work we utilised control and diabetic rats as an
experimental approach to study placental lipid metabolism at
midgestation in both healthy and diabetic pregnancies. The
diabetic model employed was obtained through neonatal
streptozotocin administration, and constitutes a mild diabetic
model previously characterised by our group (12), in which
glycemia levels (150-230 mg/dl) are similar to those
frequently found in diabetic women during pregnancy. The
objective of the present study was therefore to address a
putative role of PPARs activators as regulators of placental
lipid levels, synthesis and catabolism in placental tissues
obtained from control and diabetic rats at mid-gestation.
Materials and Methods
Animals and placental preparations
Albino Wistar rats were bred in the laboratory with free
access to Purina rat chow and water, in a lighting cycle of 14 h
light: 10 h dark. At 2 days of age, they were injected with
either streptozotocin (90 mg/kg s.c.) (Sigma, St Louis, MO,
USA) in citrate buffer (0.05 M, pH 4.5) or buffer alone (cont-
rols). Four days after birth, neonates exhibiting glycosuria
higher than 500 mg/dl were considered diabetic. The sponta-
neous evolution of this treatment leads to a diabetic state as
previously described (13). Adult diabetic rats presented
glycemia levels higher than 150 mg/dl and a marked glucose
intolerance, while control rats showed glycemia levels below
110 mg/dl. In the evening of proestrus, control and diabetic
females, weighing between 200-300 g were caged overnight
with control males. The following day was designated as day
0.5 of gestation if sperm cells were found in the vaginal smear.
A total of 50 animals were employed and 85% of them
conceived when mated in proestrous. The resorption rate was
2% in control animals and 10% in diabetic animals. Animals
were killed by cervical dislocation on day 13.5 of gestation,
and their placentas were removed and placed in Petri dishes
containing Krebs-Ringer-Bicarbonate (KRB) solution. In
this work, we utilized short term placental explant cultures to
define PPAR agonist placental effects. As PPARs may influ-
ence maternal metabolism different in vivo effects can not be
discarded. Placental explants from eight diabetic and eight
control animals were cultured for three hours in a metabolic
shaker at 37°C, either with or without PPARs agonists: clo-
fibrate (20 µM); 15-deoxyδ12,14 prostaglandin J2 (15dPGJ2,
2 µM); or carbaprostacyclin (cPGI2, 1 µM) (Cayman Chemical
Co, MI, USA). After incubation, tissues were frozen at
–70°C for further determination of lipid levels and the incu-
bating medium was preserved at –20°C for further determi-
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Tart›flma: Sonuçlar, PPAR’lerin plasentada lipid metabolizmas›n›n düzenlenmesini etkiledi¤ini kan›tlamaktad›r. Bu,
metabolizma düzenleyici yollar›n anlanmas›nda bir ilk ad›m olup, hem bu yollar›n meydana ç›kar›lmas›nda hem de
annede fleker hastal›¤› durumunda fetusa yüksek lipid yükü geçirilmesini önlemekte yararl› olabilir.
Anahtar sözcükler: gebelikte fleker hastal›¤›, plasenta lipidleri, peroksizom ço¤alt›c› hareketlendirilmifl reseptör
for the care and use of animals approved by our Institution
were followed, according to the ILAR guide for the Care and
Use of Laboratory Animals (1996), http://www.nih.gov/sigs
/bioethics/animals.html.
Determination of lipid levels
Total lipids were extracted in methanol: chloroform (2:1,
v/v) and then concentrated in a Savant Speed-Vac concentra-
tor. Triglycerides, cholesterol, cholesteryl esters and phos-
pholipids were quantified by thin layer chromatography
(TLC), stained with iodine vapour and analysed using image
analysis SIGMAGEL (Sigma, MO, USA) as reported pre-
viously (14). The placental lipids were chromatographed
with a solvent system consisting of hexane:ethyl ether:acetic
acid (80:20:2, v/v). After development, the TLC plate was
dried for 5 min in the dark under a N2 stream and lipids were
stained with iodine vapour. Lipid species were quantified by
comparison with known amounts of pure lipid standards run
on the same plate. Results are expressed as µg/mg protein
and statistically analysed by analysis of variance.
Determination of lipid synthesis
The de novo synthesis of labelled lipids from 14C-acetate was
evaluated as reported previously (14). The placental explants
from another eight diabetic and eight control animals were
cultured as described above, with the addition of 37 MBq/l
[1,2-14C]-acetate (1.96 GBq/mmol) to the incubation medium.
After incubation, tissues were washed three times to remove
adherent 14C-acetate and were then stored at -70°C until lipid
extraction. The extraction and separation of lipids by TLC
were performed as described above. All samples were
chromatographed in parallel with pure lipid standards. Ra-
dioactive spots corresponding to the different 14C-labelled li-
pid species were scraped into vials and counted in a liquid
scintillation counter. Results are expressed as dpm/µg
protein and statistically analysed by analysis of variance.
Determination of lipid catabolism
Glycerol release into the culture medium generated during
the hydrolysis of triglycerides and phospholipids in the tissues
was determined enzymatically, as reported previously
(15,16). Briefly, 0.2 ml of placental explant incubation medium
was allowed to react with 1 ml of assay solution containing
glycine (15 mg/ml), MgCl2 (0.4 mg/ml), ATP (0.75 mg/ml),
NAD+ (0.36 mg/ml), hydrazine hydrate 20% (v/v) (Sigma,
MO, USA), glycerokinase (0.42 units/ml) and glycerol-3-
phosphate dehydrogenase (2.5 units/ml) (Roche, IN, USA).
After 45 min, OD was read at 340 nm in a microtitre plate
using glycerol as the standard. Results are expressed as
nmol/mg protein and statistically analysed by analysis of
variance.
Results
In order to investigate whether PPAR ligands regulate lipid
metabolism at midgestation, both control and diabetic rat
placental explants were incubated for 3 h in KRB medium in
the presence or absence of PPARs agonists, followed by
determination of phospholipid, triglyceride, cholesterol and
cholesteryl ester levels. In the placenta from control rats, we
found that the PPARα activator clofibrate (20 µM) diminished
triglyceride (43%, p<0.01), phospholipids (63%, p<0.01) and
cholesteryl esters levels (46%, p<0.05), and did not modify
cholesterol levels (Figure 1). Differently, PPARγ agonist
15dPGJ2 (2 µM) did not modify any of the lipid species
analysed. On the other hand, the PPARδ activator cPGI2
(1 µM) reduced phospholipid levels (51%, p<0.05) and did
not modify any of the other lipid species analysed (Figure 1).
In the placenta from diabetic rats, which show increased
triglyceride (50%, p<0.05) and cholesteryl ester levels (93%,
p<0.01), the effects of PPARs agonists on lipid levels were
studied and found similar to those detected in the healthy
group. Indeed, the PPARα activator clofibrate (20 µM)
reduced triglyceride (48%, p<0.02), phospholipid (41%,
p<0.05), cholesterol (24%, p<0.05) and cholesteryl ester
levels (44%, p<0.02) in the placenta from diabetic animals.
The PPARγ ligand 15dPGJ2 (2 µM) did not modify the levels
of the studied lipids. Also, the PPARδ agonist cPGI2 reduced
phospholipid (30%, p<0.05) and cholesterol levels (35%,
p<0.05), and did not change triglyceride and cholesteryl
ester levels in the placenta from diabetic rats (Figure 1).
In order to further analyse lipid metabolic pathways, we studied
the effects of PPARs agonists on the de novo lipid synthesis by
incubating placental explants for 3 h in KRB medium con-
taining radiolabelled acetate added with or without the PPARs
ligands. In the placenta from control rats, we found that the
addition of PPARs activators reduced the de novo synthesis of
different lipid species. Indeed, clo-fibrate (20 µM) reduced the
synthesis of all lipid species analysed (triglycerides 35%,
p<0.05; phospholipids 43%, p<0.05; cholesterol 63%, p<0.02
251













Figure 1. Effect of PPARs agonists on (A) triglyceride, (B) choles-
terol, (C) cholesteryl esters and (D) phospholipid concentrations in
placental explants from control and diabetic rats. Tissues were incu-
bated for 3 h in KRB solution either with or without 20 µM clofibrate
(CL), 2 µM 15dPGJ2 (PJ) or 1 µM cPGI2, (CI). Data are the mean ±
s.e.m, n=8 in each experimental group. *p<0.05, **p<0.01 com-
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C) Cholesteryl esters D) Phospholipids
and cholesteryl esters 63%, p<0.02) (Figure 2). Also, 15dPGJ2
(2 µM) diminished the de novo synthesis of all the studied
lipids (triglycerides 57%, p<0.05; phospholipids 75%, p<0.05;
cholesterol 74%, p<0.01 and cholesteryl esters 65%, p<0.01)
(Figure 2). In addition, cPGI2 (1 µM) reduced the de novo
synthesis of triglycerides (40%, p<0.05) and phospholipids
(39%, p<0.05), without any changes in the synthesis of
cholesterol and cholesteryl esters. In the placenta from
diabetic rats, which shows a reduction in the de novo
synthesis of all lipid species analysed (triglycerides 84%,
p<0.01; phospholipids 71%, p<0.05; cholesterol 54%, p<0.05;
and cholesteryl esters 87%, p<0.001), we found that the
PPARα agonist was devoid of effect. Differently, PPARγ
agonist 15dPGJ2 (2 µM) diminished the de novo synthesis
of triglycerides (58%, p<0.05), phospholipids (58%, p<0.01)
and cholesterol (80%, p<0.01), whereas the PPARδ activator
cPGI2 (1 µM) also diminished triglycerides (58%, p<0.05),
phospholipids (51%, p<0.05) and cholesterol (74%, p<0.05)
de novo synthesis, without changing the synthesis of
cholesteryl esters (Figure 2).
To further evaluate whether PPARs activation regulates the
catabolism of esterified lipids in the placenta, placental
explants were incubated for 3 h in KRB medium either with
or without PPARs ligands and then glycerol levels released
into the incubation medium were assessed. In the placenta
from healthy animals we found that the PPARα agonist clo-
fibrate (20 µM) significantly enhanced placental lipid cata-
bolism (133%, p<0.01) (Figure 3). No modification on
glycerol release was detected in the presence of the PPARγ
agonist 15dPGJ2 (2 µM). Interestingly, an important increase
in glycerol release was found in the presence of the PPARδ
agonist cPGI2 (1 µM, 224%, p<0.001) (Figure 3). In the
diabetic group, in which a significant increase in placental
lipid catabolism was found (99%, p<0.001), we observed that
both the PPARα and PPARγ agonists employed did not
modify glycerol release. Differently, the PPARδ agonist
cPGI2 (1 µM) stimulated lipid catabolism, as indicated
by the enhanced release of glycerol (53%, p<0.01) to the
incubation medium (Figure 3).
Discussion
The results of this work reveal that the three PPARs isotypes
are indeed involved in the regulation of the placental lipid
metabolism. The placenta is an active regulator of the accretion
and transfer of lipids to the fetal circulation, and therefore a
functional regulator of the quality and quantity of lipids that
have access to the developing fetus (4).
The impact of maternal diabetes in the placental lipid meta-
bolism may be the result of the profound alterations in the
lipid profile induced by this pathology in both humans and
experimental diabetic models (4,17). In addition, the placental
derangements resulting from the increased pro-inflammatory
agents and oxidative stress in the diabetic placenta, partially
originated in an anomalous lipid profile, may lead to abnor-
malities that impair placental development, function and
metabolism (18).
As previously, in this work, too, we found that even under
moderate hyperglycemia, placental lipid metabolism is pro-
foundly affected (14). Indeed, we found increased lipid
levels and catabolism in the placenta from diabetic rats at
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Figure 3. Effect of PPARs agonists on glycerol released into the in-
cubation medium by placental explants from control and diabetic
rats. Tissues were incubated for 3 h in KRB solution either with or
without 20 µM clofibrate (CL), 2 µM 15dPGJ2 (PJ) or 1 µM cPGI2,
(CI). Data are the mean ± s.e.m, n=8 in each experimental group.
**P<0.01, ***P<0.001 compared with control without additions,
##P<0.01 compared with diabetic without additions.



















Figure 2. Effect of PPARs agonists on the de novo synthesis of (A)
triglyceride, (B) cholesterol, (C) cholesteryl esters and (D) phospho-
lipid concentrations in placental explants from control and diabetic
rats. Tissues were incubated for 3 h in KRB solution in the presence
of [1,2-14C]-acetate (1.96 GBq/mmol) either with or without 20 µM
clofibrate (CL), 2 µM 15dPGJ2 (PJ) or 1 µM cPGI2, (CI). Data are the
mean ± s.e.m, n=8 in each experimental group. *p<0.05, **p<0.01,
***p<0.001 compared with control without additions, #P<0.05,
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On the other hand, the de novo lipid synthesis is reduced in
this diabetic tissue, probably a mechanism that compensates
the increased lipid fluxes reaching the placenta from maternal
circulation. Both the increased catabolism and the reduced
de novo lipid synthesis suggest active pathways to limit over-
accumulation of placental lipids, in which PPARs appear to
be involved (14).
PPARs have been found to be elevated in trophoblastic cells
at midgestation (8). PPARγ, the best characterized isotype in
the placenta, is involved in trophoblast differentiation and
invasive behaviour (19). In the present work, we demonstrated
that each PPAR isotype activates particular and relevant
regulatory pathways in the placenta. In this tissue, PPARα
leads to a reduction in lipid levels, probably the result of a
clear catabolic effect, and also to a reduction in the de novo
lipid synthesis. Indeed, the potent catabolic effects of PPARα
are well established in different tissues (20). Alterations in
the PPARα metabolic functions in the diabetic placenta may
arise from altered levels of these nuclear receptors, as pre-
viously found for other PPAR isotypes (21), and will require
clarification through further research.
On the other hand, PPARγ, an essential receptor for placental
development, is clearly involved in adipocyte differentiation
and function (10). In this work we found that PPARγ activa-
tors did not modify placental lipid levels and catabolism, but
reduced the de novo lipid synthesis in both control and diabe-
tic placenta. Studies performed in cultured trophoblasts show
an increased uptake of fatty acids in response to PPARγ
activation (22). Therefore, the reduction of the de novo lipid
synthesis observed in our studies may be a compensatory
response to an increase in the fatty acids up-taken by the
trophoblastic cells.
Finally, the activation of PPARδ, another essential gene for
placental development, leads to catabolic effects in adipose
tissues and other cell types (11,23). We found that the
PPARδ agonist reduced phospholipid levels, probably as a
result of both an important stimulation of the catabolism of
these lipids and a reduction in the de novo lipid synthesis.
In conclusion, our data demonstrate that PPARs agonists
are important regulators of the placental lipid metabolism and
that the activation of each PPAR isotype leads to specific
effects, clearly related to different lipid metabolic pathways.
Due to the profound imbalance in lipid metabolism in the
placenta from diabetic gestations, and the possibility to
activate placental PPARs through both pharmacological
and endogenous ligands, our results reveal novel signalling
pathways that may lead to new therapeutic strategies in the re-
gulation of lipid availability to the developing fetus in diabetic
gestations.
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